^
Association details:
| Biomarker: | MEK2 F57C |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Excerpt:
We found MEK1 and MEK2 mutations in 7 of 38 Prog melanoma samples, but assigned resistance to only 3 (8%); MEK1K57E, MEK1E203K, and MEK2F57C confer resistance to BRAF inhibitors….We identified 1 patient with a MEK2F57C mutation in the pretreatment and progressing melanomas and this patient had a poor PFS (15.3 weeks) and OS (32.1 weeks).
DOI:
10.1158/1078-0432.CCR-13-3122
Source:
Title:
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Excerpt:
MEK1K57E and MEK2F57C confer melanoma cell resistance to dabrafenib.
DOI:
10.1158/1078-0432.CCR-13-3122
